Eris Lifesciences Ltd (ERIS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Eris Lifesciences Ltd (ERIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8227
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eris Lifesciences Ltd (Eris Lifesciences) is a health care products and service provider. The company offers glimepride, telmisertan, methylcobalamin and combinations, vitamin d, rabeprazole, olmesartan, mecobalamin colecalciferol, teneligliptin, rosa canina extract, cilnidipine, atorvastatin, conventional iron, gliclazide, rosuvastatin and sultamicillin products. It provides medicines to cardiovascular, anti-diabetes, vitamins and nutrients, gastroenterology, gynaecology, pediatrics, respiratory, neurology, psychiatry, and pain and analgesics. Eris Lifesciences provides anti diabities medicines such as glimepiride and combinations, teneligliptin and combinations, gliclazide and combinations and voglibose and combinations. The company offers products in the form of tablets, capsules and sachets. It markets through chemist outlets. The company has manufacturing facility located at Assam. Eris Lifesciences is headquartered in Ahmedabad, Gujarat, India.

Eris Lifesciences Ltd (ERIS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Eris Lifesciences Acquires Branded Generics Business from Strides Shasun for USD76.7 Million 12
Eris Lifesciences Acquires 40 Trademarks from Amay Pharma for USD5 Million 14
Licensing Agreements 15
Aprica Healthcare Enters into Licensing Agreement with Eris Lifesciences 15
Equity Offering 16
Eris Lifesciences Raises USD270 Million in IPO 16
Acquisition 18
Eris Lifesciences Acquires UTH Healthcare for USD2 Million 18
Eris Lifesciences Acquires Additional 14% Stake in Kinedex Healthcare for USD2 Million 19
Eris Lifesciences Acquires 61.48% Stake in Kinedex Healthcare for USD9.2 Million 20
Eris Lifesciences Acquires Aprica Healthcare 21
ChrysCapital May Sell its Stake in Eris Lifesciences 22
Nrim May Acquire Additional Stake in Kinedex Healthcare 23
Nrim Invests in Kinedex Healthcare 24
Eris Lifesciences Ltd – Key Competitors 25
Eris Lifesciences Ltd – Key Employees 26
Eris Lifesciences Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Other Significant Developments 28
Aug 17, 2017: Eris Lifesciences Announces the Dhifting of the Registered Office of the Company 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eris Lifesciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Eris Lifesciences Acquires Branded Generics Business from Strides Shasun for USD76.7 Million 12
Eris Lifesciences Acquires 40 Trademarks from Amay Pharma for USD5 Million 14
Aprica Healthcare Enters into Licensing Agreement with Eris Lifesciences 15
Eris Lifesciences Raises USD270 Million in IPO 16
Eris Lifesciences Acquires UTH Healthcare for USD2 Million 18
Eris Lifesciences Acquires Additional 14% Stake in Kinedex Healthcare for USD2 Million 19
Eris Lifesciences Acquires 61.48% Stake in Kinedex Healthcare for USD9.2 Million 20
Eris Lifesciences Acquires Aprica Healthcare 21
ChrysCapital May Sell its Stake in Eris Lifesciences 22
Nrim May Acquire Additional Stake in Kinedex Healthcare 23
Nrim Invests in Kinedex Healthcare 24
Eris Lifesciences Ltd, Key Competitors 25
Eris Lifesciences Ltd, Key Employees 26
Eris Lifesciences Ltd, Subsidiaries 27

List of Figures
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Eris Lifesciences Ltd (ERIS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Shanghai Pharmaceutical Co Ltd (601607)-製薬・医療分野:企業M&A・提携分析
    Summary Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. It carries out the research and development, manufacture and sale of pharmaceutical products for treating cancer, central nervous system (CNS) disorders and diseas …
  • Cleanup Corporation (7955):企業の財務・戦略的SWOT分析
    Cleanup Corporation (7955) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Aptose Biosciences Inc (APTO):製薬・医療:M&Aディール及び事業提携情報
    Summary Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company which focuses on diagnostics, therapies and treatment for patients with life-threatening cancers. The company advances in new therapeutics which focuses on cellular targets of cancer research coupled with companion dia …
  • Rocky Brands Inc (RCKY):企業の財務・戦略的SWOT分析
    Rocky Brands Inc (RCKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Enel Americas S.A. (ENELAM):電力:M&Aディール及び事業提携情報
    Summary Enel Americas S.A. (Enel Americas), formerly Enersis Americas S.A., is an integrated electricity utility in Latin America. The group through its subsidiaries and affiliates carries out the generation, transmission and distribution of electricity in Argentina, Brazil, Colombia and Peru. Enel …
  • Endo International Plc (ENDP):医療機器:M&Aディール及び事業提携情報
    Summary Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceutical products, generic pharmaceuticals and other products through its operating companies. It sells generic products principally in the US in various categ …
  • Uni-President Enterprises Corp:戦略・SWOT・企業財務分析
    Uni-President Enterprises Corp - Strategy, SWOT and Corporate Finance Report Summary Uni-President Enterprises Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Biotec Pharmacon ASA (BIOTEC):企業の財務・戦略的SWOT分析
    Summary Biotec Pharmacon ASA (Biotec Pharmacon) is a biopharmaceutical company that develops, manufactures and markets immune modulating compounds and cold adapted enzymes. The company provides products which are used in the areas of human medicine such as immunotherapy of cancer, general infection …
  • Tel-Instrument Electronics Corp.:企業の戦略・SWOT・財務情報
    Tel-Instrument Electronics Corp. - Strategy, SWOT and Corporate Finance Report Summary Tel-Instrument Electronics Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • A&E Medical Corp:医療機器:M&Aディール及び事業提携情報
    Summary A&E Medical Corp (A&E Medical), a subsidiary of Vance Street Capital LLC, is a medical device company that manufactures and distributes surgical equipment. The company offers products such as temporary cardiac pacing wires, sternotomy sutures, lluminated vein harvest retractors, electrosurgi …
  • China Resources Land Limited:戦略・SWOT・企業財務分析
    China Resources Land Limited - Strategy, SWOT and Corporate Finance Report Summary China Resources Land Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Digna Biotech SL-製薬・医療分野:企業M&A・提携分析
    Summary Digna Biotech SL (Digna) is a biotechnology company that specializes in the development and commercialization of robust clinical therapeutic candidates. The company’s pipeline portfolio includes cutaneous manifestation of scleroderma, clinical indications for kidney transplant and liver surg …
  • ContraFect Corp (CFRX):企業の財務・戦略的SWOT分析
    Summary ContraFect Corp (ContraFect) operates as a clinical stage biotechnology company that discovers and develops therapeutic protein and antibody products. The company develops products using lysin and monoclonal antibody platforms for the treatment of life threatening, drug-resistant infectious …
  • Aker BioMarine AS:企業の戦略・SWOT・財務分析
    Aker BioMarine AS - Strategy, SWOT and Corporate Finance Report Summary Aker BioMarine AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • InvitroCue Ltd (IVQ):企業の財務・戦略的SWOT分析
    Summary InvitroCue Ltd (InvitroCue), formerly Bunuru Corporation Ltd, is a provider of bio-analytic solutions. The company provides digital pathology services such as digitization, sample preparation, staining, computer aided diagnosis and consultation, telepathology, automated reporting and image a …
  • University of Florida-製薬・医療分野:企業M&A・提携分析
    Summary University of Florida (UF) is an educational institute that offers undergraduate, graduate and distance learning programs. The institute offers educational programs in areas of agricultural, business administration, journalism and communications, law, dentistry, arts and sciences, medicine, …
  • Aptitude Medical Systems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aptitude Medical Systems Inc (Aptitude Medical) is a developer of dynamic proteins, lipids, sugars and metabolites. The company's target range comprises nonimmunogenic proteins, peptides, toxins, glycans, drugs, metabolites and small epitopes. Its integrated suite of proprietary technologies …
  • Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析
    Summary Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that discover, develops and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as chronic hepatitis B virus (HBV) and microbioti …
  • AeroCentury Corp.:企業の戦略・SWOT・財務情報
    AeroCentury Corp. - Strategy, SWOT and Corporate Finance Report Summary AeroCentury Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Constellium NV:企業の戦略・SWOT・財務情報
    Constellium NV - Strategy, SWOT and Corporate Finance Report Summary Constellium NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆